Study guide
10.4 Research Governance, Institutional Review Boards (IRB) & Scientific Integrity
Certified in Executive Nursing Practice CENP
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
0.1 Overview of the AONL CENP Certification & Executive Competencies 0.2 Executive Study Strategy, Exam Format & Question Analysis
2 Executive Communication & Stakeholder Engagement
1.1 Executive Communication Channels, Framing & Board-Level Presentation 1.2 Crisis Communication, Media Relations & High-Stakes Public Messaging 1.3 Interprofessional Collaboration & Physician-Executive Alignment 1.4 Community, Patient & Family Engagement in System Governance
3 Relationship Management & Shared Governance
2.1 Shared Governance Structures, Council Charters & Staff Empowerment 2.2 Labor Relations, Collective Bargaining & Union-Management Engagement 2.3 Inter-Departmental Alignment & Executive Peer Collaboration 2.4 Academic-Practice Partnerships & Nursing Workforce Pipelines
4 Influencing Behaviors, Conflict Resolution & Negotiation
3.1 Negotiation Strategies, Principled Bargaining & Coalition Building 3.2 Conflict Management Models & Resolving Executive Disputes 3.3 Building Trust, Executive Credibility & Psychological Safety
5 Regulatory, Legal & Accreditation Compliance
4.1 The Joint Commission Standards, National Performance Goals & Survey Readiness 4.2 CMS Conditions of Participation, Deemed Status & System Compliance 4.3 Healthcare Law: EMTALA, HIPAA, Stark Law, Anti-Kickback & False Claims Act 4.4 State Nurse Practice Acts, Mandatory Staffing Laws & Scope of Practice Oversight
6 Patient Safety, Risk Management & High Reliability
5.1 High Reliability Organizing (HRO) Principles & Just Culture Implementation 5.2 Proactive Risk Assessment (FMEA) vs Reactive Root Cause Analysis (RCA2) 5.3 Enterprise Risk Management, Sentinel Events & Patient Safety Organizations (PSOs) 5.4 Improvement Science: Model for Improvement, PDSA, Lean, Six Sigma & Gap Analysis
7 Healthcare Economics, Payment Models & Clinical Quality
6.1 Healthcare Financing: DRGs, Inpatient Prospective Payment & Cost Allocation 6.2 Value-Based Purchasing, Hospital Readmissions Reduction (HRRP) & HACRP 6.3 Nursing Quality Measurement: NDNQI, HCAHPS, Leapfrog & Evidence-Based Practice (EBP) 6.4 Care Delivery Models, Top-of-License Practice & Population Health
8 Executive Leadership Theories & Strategic Thinking
7.1 Transformational, Servant & Situational Leadership in Executive Nursing 7.2 Systems Thinking, Complexity Science & Navigating Unintended Consequences 7.3 Emotional Intelligence, Executive Presence & Resilient Leadership 7.4 Strategic Environmental Scanning: PESTEL, SWOT & Market Analysis 7.5 Executive Decision-Making, Delegation & Acting Under Uncertainty
9 Strategic Planning, Execution & Innovation
8.1 Formulating System Strategic Plans, Mission/Vision Alignment & Cascading Goals 8.2 The Balanced Scorecard & Key Performance Indicator (KPI) Architecture 8.3 Leading Transformational Change: Kotter's 8-Step and Lewin's Change Models 8.4 Fostering Clinical Innovation, Disruptive Technology & Innovation Adoption (Rogers)
10 Succession Planning, Talent Architecture & Culture
9.1 Executive Succession Planning & Nursing Leadership Pipelines 9.2 Mentorship, Executive Coaching & Leadership Competency Development 9.3 Shaping Organizational Culture, Retention Strategies & Clinician Well-Being 9.4 Inclusion, Belonging & Bias Mitigation in the Workforce and Business Operations 9.5 Healthy Work Environments: AACN Standards, Assessment & Workplace Violence Prevention
11 Ethical Governance & Professional Accountability
10.1 The ANA Code of Ethics for Nurse Executives & Ethical Dilemmas 10.2 Moral Distress, Moral Courage & Establishing Ethics Advisory Committees 10.3 Whistleblower Protections, Corporate Compliance & Conflicts of Interest 10.4 Research Governance, Institutional Review Boards (IRB) & Scientific Integrity
12 Advocacy, Health Equity & Professional Advancement
11.1 Legislative Advocacy, Health Policy Engagement & Grassroots Action 11.2 Advancing Health Equity, Social Determinants of Health (SDOH) & Community Impact 11.3 Contributing to the Profession, Professional Associations & Advancing Nursing Science
13 Healthcare Financial Management & Operations Budgeting
12.1 Healthcare Financial Statements: Balance Sheet, Income Statement & Cash Flow 12.2 Operating Budget Formulation: Volume Forecasting, Revenues & Expense Management 12.3 Budget Methodologies: Incremental, Zero-Based & Activity-Based Budgeting 12.4 Variance Analysis: Volume, Price/Rate & Efficiency Variances in Nursing Operations
14 Capital Budgeting, Financial Analysis & Contracting
13.1 Capital Budgeting: Net Present Value (NPV), Internal Rate of Return (IRR) & Payback 13.2 Breakeven Analysis, Contribution Margin & Fixed vs Variable Costs 13.3 Vendor Contracting, Request for Proposals (RFP) & System Supply Chain Resilience
15 Human Resource Economics, Staffing Models & Informatics
14.1 Workforce Planning, FTE Calculations, HPPD & Productive vs Non-Productive Time 14.2 Dynamic Staffing Methodologies, Acuity-Based Scheduling & Float Pool Economics 14.3 Health Informatics Governance, Electronic Health Record (EHR) Optimization & Clinical Decision Support (CDS) 14.4 Talent Acquisition, Onboarding, Performance Evaluation & Employment Law
10.4 Research Governance, Institutional Review Boards (IRB) & Scientific Integrity
Key Takeaways Explain This Topic AI
The Belmont Report (1979) articulates the three foundational ethical principles governing human subjects research: Respect for Persons (autonomy and voluntary informed consent), Beneficence (maximizing benefits while minimizing risks), and Justice (equitable distribution of research burdens and benefits).
Institutional Review Boards (IRBs), established under Title 45 CFR Part 46 (The Common Rule), classify research reviews into three regulatory tiers based on risk: Exempt (minimal risk in defined categories), Expedited (no more than minimal risk in listed categories), and full board (greater than minimal risk or otherwise ineligible for expedited review).
The federal definition of research misconduct (42 CFR Part 93) is strictly limited to fabrication, falsification, and plagiarism (FFP) in proposing, performing, or reviewing research, and expressly excludes honest error or legitimate differences of opinion.
Nurse executives must enforce rigorous governance rubrics that differentiate clinical research (systematic investigations generating generalizable knowledge) from Quality Improvement (QI) and Evidence-Based Practice (EBP) (local, context-specific process optimizations).
Fostering a Magnet®-recognized nursing research culture requires executive sponsorship, establishing a Nursing Research Council, securing intramural seed funding, and establishing synergistic collaborative partnerships between PhD-prepared nurse scientists and DNP-prepared clinical leaders.
Last updated: October 2026
10.4 Research Governance, Institutional Review Boards (IRB) & Scientific Integrity
Note
The Executive Mandate in Clinical Inquiry and Scientific Governance In high-performing, Magnet®-recognized healthcare systems, clinical inquiry is the engine of quality, innovation, and evidence-based practice. Nurse executives are responsible for creating an environment where nursing science flourishes while ensuring absolute adherence to federal research regulations, ethical standards, and scientific integrity. Whether clinical inquiry involves clinical drug trials, nursing intervention studies, doctoral dissertations (PhD/DNP), or quality improvement initiatives, executive leaders must ensure that human subjects are protected from exploitation, research protocols comply with Title 45 Code of Federal Regulations Part 46 (The Common Rule), and Institutional Review Board (IRB) governance functions with impeccable rigor.
To lead academic medical centers and community health systems effectively, the nurse executive must master the philosophical foundations of research ethics, federal regulatory classifications, scientific misconduct management, and the operational boundaries between research and quality improvement.
Historical Foundations & The Belmont Report
Modern research ethics arose in response to egregious historical atrocities committed in the name of biomedical science. The Nuremberg Code (1947) was drafted following the horrific human experimentation conducted by Nazi physicians during World War II, establishing that voluntary, informed consent is absolutely essential. Decades later, public revelation of the United States Public Health Service Syphilis Study at Tuskegee (1932–1972)—in which impoverished African American men were deliberately misled, denied penicillin therapy, and observed for long-term syphilis pathology—galvanized federal intervention.
Congress passed the National Research Act of 1974, establishing the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. In 1979, the Commission published The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research , which remains the cornerstone of federal research governance. +-------------------------------------------------------------------------+
- | THE BELMONT REPORT ETHICAL TRIAD |
- | |
- | 1. RESPECT FOR PERSONS -> Autonomy & Voluntariness |
- | * Acknowledge personal autonomy of moral agents |
- | * Provide additional protections for vulnerable populations |
- | * Operationalized via rigorous, voluntary INFORMED CONSENT |
- | |
- | 2. BENEFICENCE -> Maximize Benefits & Minimize Harms |
- | * Obligation to 'do no harm' and maximize potential goods |
- | * Systematic, objective assessment of risk/benefit ratios |
- | * Operationalized via RESEARCH PROTOCOL RISK MANAGEMENT |
- | |
- | 3. JUSTICE -> Fairness in Distribution |
- | * Fair selection of research subjects without bias |
- | * Equitable distribution of research burdens and benefits |
- | * Operationalized via INCLUSIVE, NON-EXPLOITATIVE SAMPLING |
- +-------------------------------------------------------------------------+
- Application of Belmont Principles
Respect for Persons: Requires that individuals be treated as autonomous agents capable of deciding whether to participate in research. For individuals with diminished autonomy (e.g., children, prisoners, individuals with cognitive impairments, or critically ill patients), intensive protective safeguards must be mandated. Informed consent must include full disclosure of study aims, procedures, foreseeable risks, potential benefits, alternatives, voluntary participation, and the absolute right to withdraw at any time without penalty.
Beneficence: Investigators must systematically assess risks (physical, psychological, sociological, legal, and economic) and take proactive steps to minimize them. Research is ethically justifiable only if the anticipated benefits to the subject or the generalizable societal knowledge clearly outweigh the potential risks.
Justice: Concerns who bears the burdens of research versus who reaps its benefits. The Belmont Report explicitly prohibits selecting research subjects based on convenience, poverty, racial marginalization, or institutionalization (such as selecting prisoners or Medicaid patients to test dangerous procedures whose benefits will accrue exclusively to affluent populations).
Federal Regulatory Architecture: 45 CFR 46 (The Common Rule)
The Belmont Report's ethical principles were codified into federal statutory regulation under Title 45 of the Code of Federal Regulations, Part 46 (45 CFR 46) , known as The Common Rule . Overseen by the HHS Office for Human Research Protections (OHRP), the Common Rule has been formally adopted by 20 federal departments and agencies funding human subjects research (e.g., NIH, CDC, VA, DOD).
Specialized Subparts for Vulnerable Populations
In addition to general requirements (Subpart A), 45 CFR 46 establishes explicit, heightened protections for vulnerable groups:
Subpart B: Additional Protections for Pregnant Women, Human Fetuses, and Neonates Involved in Research;
Subpart C: Additional Protections Pertaining to Biomedical and Behavioral Research Involving Prisoners (strictly limiting research to conditions affecting prisoners as a class);
Subpart D: Additional Protections for Children Involved as Subjects in Research (mandating parental permission and child assent calibrated to developmental maturity).
Key Provisions of the Revised Common Rule
The 2018 Revised Common Rule modernized research governance by requiring:
Broad Consent: Establishing regulatory standards for obtaining prospective, broad consent for the secondary storage and research use of identifiable biospecimens and data;
Single IRB (sIRB) Mandate: Mandating that multi-institution cooperative research studies located in the United States utilize a single IRB of record to streamline oversight and eliminate duplicative reviews;
Posting of Informed Consent Forms: Mandating that for federally funded clinical trials, one completed, IRB-approved informed consent form must be posted on a publicly available federal website (such as ClinicalTrials.gov) after trial recruitment closes.
Institutional Review Board (IRB) Oversight & Levels of Review
An Institutional Review Board (IRB) is an administrative body established to protect the rights, safety, and welfare of human subjects recruited to participate in research activities conducted under the auspices of the institution.
IRB Composition Mandates
Under 45 CFR § 46.107, an IRB must consist of:
- At least five members with diverse backgrounds, professional training, and demographic representation;
- At least one member whose primary concerns are scientific (e.g., physician, nurse scientist, pharmacologist);
- At least one member whose primary concerns are non-scientific (e.g., ethicist, attorney, chaplain);
At least one member who is completely unaffiliated with the institution and not part of the immediate family of an affiliated member (representing community interests);
Mandatory recusal: No IRB member may participate in the initial or continuing review of any project in which the member has a conflicting financial or professional interest. +-------------------------------------------------------------------------+
- | THE THREE TIERS OF IRB REVIEW |
- | |
- | [EXEMPT REVIEW] |
- | * Minimal risk; falls under 8 specific federal regulatory categories |
- | * Examples: Anonymous surveys, educational tests, secondary analysis |
- | of existing de-identified data, benign behavioral interventions |
- | * Evaluated by IRB chair or designated compliance officer (NOT self!) |
- | |
- | [EXPEDITED REVIEW] |
- | * No more than minimal risk; falls into specific federal categories |
- | * Examples: Routine blood draws within volume limits, non-invasive |
- | biological sensors, voice/digital recordings, focus groups |
- | * Evaluated by IRB chair or single experienced voting member |
- | |
- | [FULL BOARD / CONVENED REVIEW] |
- | * Greater than minimal risk (and some vulnerable-population studies) |
- | * Examples: Investigational new drugs/devices (IND/IDE), invasive |
- | biopsies, clinical trials on children/prisoners/ICU patients |
- | * Evaluated by a convened quorum at a formal, minuted IRB meeting |
- +-------------------------------------------------------------------------+
IRB Review Level Risk Threshold Regulatory Criteria Common Nursing Research Scenarios
Exempt Review Less than or equal to minimal risk. Falls into one of 8 categories under 45 CFR § 46.104. Retrospective chart review of fully de-identified EHR data; anonymous nursing burnout surveys without identifiers.
Expedited Review No more than minimal risk. Falls into categories under 45 CFR § 46.110. Does not involve invasive interventions. Drawing 20 mL of blood from healthy nurses to study stress biomarkers; testing non-invasive biometric sleep trackers on night-shift staff.
Full Board Review Greater than minimal risk, or otherwise ineligible for expedited review. Mandates convened quorum of members under 45 CFR § 46.108. Evaluating a novel nurse-administered sedative protocol in mechanically ventilated ICU patients; clinical trials involving pediatric oncology patients.
Tip
Minimal Risk Benchmark Under federal regulations, Minimal Risk means that the probability and magnitude of harm or discomfort anticipated in the research are not greater in and of themselves than those ordinarily encountered in daily life or during the performance of routine physical or psychological examinations or tests . If research exceeds this threshold, full board review is required.
Scientific Integrity & Managing Research Misconduct
Nurse executives are responsible for protecting the scientific integrity of all research conducted within the health system. Federal regulations promulgated by the Public Health Service (PHS) and HHS Office of Research Integrity (ORI) under 42 CFR Part 93 establish strict definitions and procedures for addressing research misconduct.
The Federal Definition of Research Misconduct
Research misconduct is formally defined as Fabrication, Falsification, or Plagiarism (FFP) in proposing, performing, or reviewing research, or in reporting research results:
Fabrication: Making up data or results and recording or reporting them;
Falsification: Manipulating research materials, equipment, or processes, or changing or omitting data or results such that the research is not accurately represented in the research record;
Plagiarism: The appropriation of another person's ideas, processes, results, or words without giving appropriate credit.
Critical Regulatory Exclusion: Research misconduct does not include honest error or differences of opinion . To establish a finding of research misconduct, there must be a significant departure from accepted practices of the relevant research community, committed intentionally, knowingly, or recklessly, proven by a preponderance of the evidence.
The Institutional Misconduct Response Procedure
When an allegation of scientific misconduct surfaces, the institution must follow a multi-stage procedural sequence:
Assessment: A documented preliminary determination by the research integrity officer whether the allegation falls within the definition of research misconduct and is specific and credible enough to warrant an inquiry.
Inquiry: A confidential fact-finding review to determine whether an investigation is warranted. Under ORI's revised rule (applying to allegations received on or after January 1, 2026) the inquiry generally must be completed within 90 days (previously 60).
Investigation: A comprehensive investigation by a committee with appropriate scientific expertise, generally completed within 180 days (previously 120), examining research records, notebooks, audit logs, code and raw data.
Findings and Reporting: The institution reports its investigation to the HHS Office of Research Integrity (ORI), which makes federal findings and may impose administrative actions (such as supervision requirements or debarment); the institution may separately impose its own sanctions and correct the research record, for example by requesting retractions.
Differentiating Research, Quality Improvement (QI) & Evidence-Based Practice (EBP)
One of the most complex governance dilemmas confronting executive nurse leaders is differentiating between Clinical Research , Quality Improvement (QI) , and Evidence-Based Practice (EBP) . While all three methodologies utilize data, their fundamental intent, regulatory oversight, and ethical frameworks diverge significantly. +-------------------------------------------------------------------------+
- | QI vs. EBP vs. CLINICAL RESEARCH COMPARISON |
- | |
- | [CLINICAL RESEARCH] |
- | * Intent: Generate generalizable new scientific knowledge. |
- | * Scope: Broad, universal application across populations. |
- | * Design: Experimental, control groups, randomized trials. |
- | * Oversight: Mandatory IRB oversight under 45 CFR 46. |
- | |
- | [EVIDENCE-BASED PRACTICE (EBP)] |
- | * Intent: Translate existing external scientific evidence to care. |
- | * Scope: Unit- or hospital-level clinical workflow improvement. |
- | * Design: Synthesis of literature, pilot testing, practice change. |
- | * Oversight: Clinical Practice Council; usually exempt/non-research. |
- | |
- | [QUALITY IMPROVEMENT (QI)] |
- | * Intent: Improve specific, local operational process or outcome. |
- | * Scope: Internal healthcare microsystem (specific unit or clinic). |
- | * Design: Rapid PDSA cycles, Lean/Six Sigma, run charts. |
- | * Oversight: Quality Governance; non-human subjects research. |
- +-------------------------------------------------------------------------+
When Does QI Cross the Threshold into Research?
A project begins as Quality Improvement when the intent is strictly internal operational optimization (e.g., standardizing a central line dressing change kit to reduce CLABSI on a surgical unit). However, the project crosses into clinical research requiring IRB review if:
The methodology involves withholding an established standard of care from a control group to evaluate comparative effectiveness;
Patients are subjected to experimental, unproven interventions carrying incremental physiological or psychological risks;
The primary aim is explicitly designed to generate generalizable scientific theory rather than local operational improvement.
Note
Intent to Publish Does NOT Equal Research A widespread misconception in healthcare is that if clinical leaders intend to publish the results of a QI project in a peer-reviewed journal, the project automatically constitutes research requiring prospective IRB approval. The HHS OHRP has explicitly clarified that the intent to publish or present QI findings at a national conference does not, by itself, convert a QI project into human subjects research . If the underlying intent was local process improvement and no experimental risks were introduced, publication is entirely permissible without prior research classification.
Executive Sponsorship of Nursing Inquiry & Magnet® Alignment
To build a premier clinical enterprise, the Chief Nursing Officer must actively sponsor and resource nursing inquiry across all operational service lines. Under the American Nurses Credentialing Center (ANCC) Magnet Recognition® model, the component New Knowledge, Innovations, and Improvements (NKII) mandates that health systems demonstrate empirical evidence of nurse-led research and widespread EBP dissemination.
PhD and DNP Collaboration Architecture
High-performing nurse executives resolve professional silos by pairing Doctor of Philosophy (PhD) nurse scientists with Doctor of Nursing Practice (DNP) executive and clinical leaders:
PhD Nurse Scientists: Specialize in scientific discovery, advanced experimental design, external federal grant procurement (e.g., NIH/NINR R01 grants), and generating generalizable nursing science.
DNP Clinical Leaders: Specialize in implementation science, systems leadership, translation of empirical research into bedside clinical pathways, and leading robust QI initiatives.
The Nursing Research Council (NRC): The CNO establishes an institutional NRC that reviews proposed nursing inquiry, provides biostatistical support, navigates IRB submissions, awards intramural seed grants, and mentors frontline staff nurses in presenting podium and poster abstracts at national symposia.